MCID: PSY004
MIFTS: 72

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Psychotic Disorders 43 73
Mental or Behavioural Disorder 12
Mental Disorders 73
Psychotic 55

Classifications:

ICD10: 33


Summaries for Psychotic Disorder

MedlinePlus : 43 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophreniform disorder and delusional disorder, and has symptoms including photophobia, agitation and lethargy. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Neuroscience and Circadian entrainment. The drugs Methylprednisolone hemisuccinate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Wikipedia : 76 Psychosis is an abnormal condition of the mind that results in difficulties determining what is real and... more...

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 33.2 PRL NRG1 DRD2 COMT
2 delusional disorder 32.2 DRD2 DRD3 DRD4
3 schizoaffective disorder 31.6 SLC6A4 SLC1A1 PRODH PRL HTR2A DTNBP1
4 schizophrenia 31.2 SLC6A4 SLC1A1 SHANK3 RGS4 RELN PRODH
5 anxiety 30.8 BDNF COMT HTR2A SLC6A4
6 depression 30.7 BDNF HTR2A RELN SLC6A4
7 traumatic brain injury 30.6 BDNF COMT DRD2
8 brain injury 30.6 BDNF COMT DRD2
9 tardive dyskinesia 30.3 HTR2A DRD3 DRD2 COMT
10 substance abuse 30.3 SLC6A4 PRL DRD4 DRD3 DRD2 COMT
11 personality disorder 30.2 SLC6A4 PRL HTR2A DRD4 DRD2 COMT
12 mental depression 30.2 SLC6A4 HTR2A COMT BDNF
13 borderline personality disorder 30.1 SLC6A4 HTR2A COMT BDNF
14 postpartum depression 30.1 SLC6A4 PRL COMT BDNF
15 temporal lobe epilepsy 30.1 BDNF RELN SLC1A1
16 post-traumatic stress disorder 30.0 SLC6A4 MAOB HTR2A DRD2 COMT BDNF
17 mood disorder 30.0 SLC6A4 MAOB HTR2A DRD4 DRD3 DRD2
18 galactorrhea 30.0 DRD2 PRL
19 alexithymia 30.0 COMT DRD2 SLC6A4
20 asperger syndrome 29.9 BDNF DISC1 SHANK3 SLC6A4
21 cocaine dependence 29.9 DRD2 DRD3 SLC6A4
22 tic disorder 29.9 DRD2 DRD4 HTR2A
23 paranoid schizophrenia 29.9 SLC6A4 HTR2A COMT BDNF
24 early-onset schizophrenia 29.9 HTR2A DRD2 BDNF
25 autism spectrum disorder 29.9 SLC6A4 SHANK3 RELN NRXN1 HTR2A BDNF
26 substance-induced psychosis 29.9 DRD2 HTR2A
27 endogenous depression 29.9 BDNF HTR2A SLC6A4
28 obsessive-compulsive disorder 29.8 SLC6A4 SLC1A1 PRL HTR2A DRD4 DRD3
29 major depressive disorder 29.8 SLC6A4 PRL HTR2A DRD4 DRD3 DRD2
30 drug dependence 29.7 BDNF DRD2 DRD3 SLC6A4
31 eating disorder 29.7 BDNF COMT DRD2 SLC6A4
32 alcohol dependence 29.7 SLC6A4 MAOB HTR2A DRD4 DRD3 DRD2
33 serotonin syndrome 29.7 HTR2A MAOB SLC6A4
34 heroin dependence 29.7 BDNF DRD2 DRD4
35 conduct disorder 29.6 SLC6A4 DRD4 DRD2 COMT
36 disease of mental health 29.6 SLC6A4 SHANK3 RELN NRXN1 NRG1 HTR2A
37 pervasive developmental disorder 29.6 SLC6A4 SHANK3 RELN NRXN1 BDNF
38 tobacco addiction 29.6 SLC6A4 NRXN1 HTR2A DRD2 COMT
39 bipolar i disorder 29.6 SLC6A4 NRG1 HTR2A DTNBP1 DAO COMT
40 autism 29.6 SLC6A4 SHANK3 RELN NRXN1 HTR2A DRD4
41 substance dependence 29.6 SLC6A4 DRD4 DRD3 DRD2 BDNF
42 bipolar disorder 29.5 SLC6A4 SHANK3 RGS4 RELN PRODH PRL
43 alcohol abuse 29.5 SLC6A4 PRL HTR2A DRD4 DRD3 DRD2
44 attention deficit-hyperactivity disorder 29.5 SLC6A4 MAOB HTR2A DRD4 DRD3 DRD2
45 parkinson disease, late-onset 29.4 SLC6A4 MAOB HTR2A DRD3 DRD2 COMT
46 drug psychosis 11.2
47 norrie disease 11.2
48 kifafa seizure disorder 11.1
49 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 10.9
50 phenylketonuria 10.9

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


photophobia, agitation, lethargy, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, nervousness, mental and behavioral signs and symptoms, forgetful, decrease in appetite, feeling jittery, symptoms, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, catatonic reaction

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 PRODH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.36 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.36 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.36 DRD3 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 DRD3 DRD4 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.36 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.36 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT DAO DISC1 DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.16 BDNF COMT DAO DISC1 DRD2 DRD3
3 nervous system MP:0003631 9.89 BDNF COMT DAO DISC1 DRD2 DRD3
4 integument MP:0010771 9.81 BDNF DRD2 DTNBP1 PRL PRODH RELN
5 renal/urinary system MP:0005367 9.17 COMT DRD2 DRD3 DTNBP1 MAOB RGS4

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1057)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone hemisuccinate Approved Phase 4,Phase 1,Phase 2 2921-57-5
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 1,Phase 2 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
5
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
6
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 65576-45-6, 85650-56-2 3001386
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
8
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 146939-27-7 60854
9
Linagliptin Approved Phase 4,Phase 1 668270-12-0 10096344
10
Sulpiride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15676-16-1 5355
11
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-86-8 3559
12
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
13
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 298-46-4 2554
14
Coal tar Approved Phase 4,Phase 2,Not Applicable 8007-45-2
15
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
16
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 554-13-2
17
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
18
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
19
Zolpidem Approved Phase 4,Phase 3,Phase 2,Not Applicable 82626-48-0 5732
20
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
21
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
22
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-53-3 2726
23
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 112111-43-0
24
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
25
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
26
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29110-47-2 3519
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
28
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
29
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5786-21-0 2818
30
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
31
Reboxetine Approved, Experimental Phase 4,Phase 2,Phase 1,Not Applicable 98769-81-4, 71620-89-8 123628 65856
32
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 10118-90-8 5281021
33
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
34
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
35
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
36
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
37
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
38
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 148553-50-8 5486971
39
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
40
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
42 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
44
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
45
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 93-14-1 3516
46
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 249296-44-4 5310966
47
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1972-08-3 16078
48
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28981-97-7 2118
49
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
50
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
3 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
4 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
5 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
6 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
7 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
8 Linagliptin and Mesenchymal Stem Cells: A Pilot Study Unknown status NCT02442817 Phase 4 Linagliptin
9 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
10 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
11 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
12 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
13 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
15 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
16 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
17 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
18 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
19 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
20 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
21 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
22 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
23 Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch Unknown status NCT02697045 Phase 4 Aripiprazole 400mg LAI
24 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
25 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
26 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
27 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
28 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
29 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
30 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
31 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
32 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
33 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
34 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
35 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
36 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
37 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
38 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
39 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
40 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
41 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
42 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
43 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
44 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
45 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
46 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
47 Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Unknown status NCT01708837 Phase 4 Propofol
48 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Unknown status NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
49 Impaired Decision Making in Pedophilic Offenders Unknown status NCT01541150 Phase 4
50 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

41
Brain, Testes, Skin, Heart, Pituitary, Temporal Lobe, Bone

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 1366)
# Title Authors Year
1
Speech structure links the neural and socio-behavioural correlates of psychotic disorders. ( 30017778 )
2019
2
Cannabis-related psychotic disorder upon relapse to cannabis use: A case series and possible neurobiological implications. ( 29524790 )
2018
3
Mentalizing impairment as a mediator between reported childhood abuse and outcome in nonaffective psychotic disorder. ( 29145104 )
2018
4
No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. ( 29482043 )
2018
5
Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder. ( 29807805 )
2018
6
Treatment of a Patient with Psychotic Disorder Undergoing Haemodialysis: a Case Report. ( 29864754 )
2018
7
Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults. ( 29361848 )
2018
8
Sibling bullying in middle childhood and psychotic disorder at 18 years: a prospective cohort study. ( 29429415 )
2018
9
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. ( 29387876 )
2018
10
Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors. ( 29174764 )
2018
11
Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. ( 29643331 )
2018
12
Is BDNF-Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population-based cohort study. ( 29785763 )
2018
13
Prevalence Rate and Risk Factors of Victimization in Adult Patients With a Psychotic Disorder: A Systematic Review and Meta-analysis. ( 29547958 )
2018
14
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. ( 29401155 )
2018
15
The development of an occupational therapy intervention for adults with a diagnosed psychotic disorder following discharge from hospital. ( 29721331 )
2018
16
Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. ( 29798730 )
2018
17
Childhood trauma- and cannabis-associated microstructural white matter changes in patients with psychotic disorder: a longitudinal family-based diffusion imaging study. ( 29807550 )
2018
18
Risk of non-affective psychotic disorder or bipolar disorder in autism spectrum disorder: a longitudinal register-based study in the Netherlands. ( 30460888 )
2018
19
Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. ( 30113282 )
2018
20
Out-of-pocket health expenditures in patients with bipolar disorder, anxiety, schizophrenia and other psychotic disorders: findings from a study in a psychiatry outpatient clinic in Turkey. ( 29184969 )
2018
21
Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders. ( 29329043 )
2018
22
Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome. ( 29593589 )
2018
23
Motor activity patterns in acute schizophrenia and other psychotic disorders can be differentiated from bipolar mania and unipolar depression. ( 30312969 )
2018
24
Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. ( 29984888 )
2018
25
Psychotic disorder symptom rating scales: Are dichotomous or multi-point scales more clinically useful?-An ICD-11 field study. ( 30017460 )
2018
26
ACUTE SCHIZOPHRENIA-LIKE PSYCHOTIC DISORDER: A CRITICAL APPRAISAL OF ITS DIAGNOSTIC VALIDITY THROUGH A CASE SERIES. ( 30023137 )
2018
27
The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. ( 30041133 )
2018
28
Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study. ( 30211136 )
2018
29
Acute Polymorphic Psychotic Disorder: Concepts, Empirical Findings, and Challenges for ICD-11. ( 30256333 )
2018
30
Corrigendum to "Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder" [Schizophr. Res. 193 (2018) 173-181]. ( 30314649 )
2018
31
Shared psychotic disorder in children and young people: a systematic review. ( 30328525 )
2018
32
An implicit threat: dolutegravir-induced schizophrenic brief psychotic disorder and persistent cenesthopathy. ( 30407255 )
2018
33
Care of Youth in Their First Emergency Presentation for Psychotic Disorder: A Population-Based Retrospective Cohort Study. ( 30418709 )
2018
34
Characteristics and outcomes of young people with substance induced psychotic disorder. ( 30471979 )
2018
35
Correction: Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study. ( 30475906 )
2018
36
BEATVIC, a body-oriented resilience therapy using kickboxing exercises for people with a psychotic disorder: a feasibility study. ( 30537937 )
2018
37
Electrocortical Responses to Emotional Stimuli in Psychotic Disorders: Comparing Schizophrenia Spectrum Disorders and Affective Psychosis. ( 30505284 )
2018
38
Intellectual Disability and Psychotic Disorders in Children: Association With Maternal Severe Mental Illness and Exposure to Obstetric Complications in a Whole-Population Cohort. ( 30278792 )
2018
39
Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. ( 30273898 )
2018
40
Does Residential Green and Blue Space Promote Recovery in Psychotic Disorders? A Cross-Sectional Study in the Province of Utrecht, The Netherlands. ( 30297637 )
2018
41
City Living and Psychotic Disorders-Implications of Global Heterogeneity for Theory Development. ( 30304485 )
2018
42
VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study. ( 30310054 )
2018
43
An association between YKL-40 and type 2 diabetes in psychotic disorders. ( 30328100 )
2018
44
The Incidence of Nonaffective, Nonorganic Psychotic Disorders in Older People: A Population-based Cohort Study of 3 Million People in Sweden. ( 30339239 )
2018
45
Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. ( 30343458 )
2018
46
Predicting Unsuccessful Clozapine Treatment After First Use in Adult Patients With Psychotic Disorders. ( 30371636 )
2018
47
Childhood Trauma and Neurocognition in Adults With Psychotic Disorders: A Systematic Review and Meta-analysis. ( 30376115 )
2018
48
Association between family history of mental disorders and outcome in psychotic disorders. ( 30384280 )
2018
49
The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. ( 30409537 )
2018
50
Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders. ( 30415175 )
2018

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.09 COMT DTNBP1 RGS4 SHANK3 SLC1A1
2
Show member pathways
12.04 COMT DRD2 DRD3 DRD4 MAOB SHANK3
4
Show member pathways
11.74 BDNF DRD2 MAOB
5 11.71 HTR2A MAOB SLC6A4
6 11.64 DRD3 DRD4 HTR2A
7
Show member pathways
11.62 DRD2 DRD3 DRD4
8
Show member pathways
11.32 DRD2 DRD3 DRD4 HTR2A
9
Show member pathways
11.19 DAO MAOB PRODH
10
Show member pathways
10.58 COMT MAOB
11 10.51 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.97 DRD2 DRD3 DRD4 HTR2A NRG1 NRXN1
2 postsynaptic density GO:0014069 9.83 DISC1 DRD2 DTNBP1 SHANK3
3 postsynaptic membrane GO:0045211 9.8 COMT DISC1 DTNBP1 SHANK3
4 axon GO:0030424 9.8 BDNF COMT DRD2 DTNBP1 HTR2A NRG1
5 dendritic spine GO:0043197 9.71 COMT DRD2 DTNBP1 SHANK3
6 endocytic vesicle GO:0030139 9.65 DRD2 DRD3 NRXN1
7 integral component of postsynaptic membrane GO:0099055 9.61 DRD2 HTR2A SLC6A4
8 GABA-ergic synapse GO:0098982 9.56 DRD2 DRD3 NRG1 NRXN1
9 dopaminergic synapse GO:0098691 9.51 DRD2 DRD3
10 dendrite GO:0030425 9.5 BDNF COMT DRD2 DRD4 HTR2A RELN
11 integral component of presynaptic membrane GO:0099056 9.46 DRD2 HTR2A NRXN1 SLC6A4
12 glutamatergic synapse GO:0098978 9.17 DRD2 DRD3 DRD4 DTNBP1 HTR2A NRG1
13 plasma membrane GO:0005886 10.27 COMT DISC1 DRD2 DRD3 DRD4 DTNBP1

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.97 BDNF NRXN1 RELN SHANK3
2 response to drug GO:0042493 9.95 COMT DRD2 DRD3 HTR2A MAOB PRL
3 response to ethanol GO:0045471 9.91 DRD2 DRD3 MAOB PRL RGS4
4 cellular calcium ion homeostasis GO:0006874 9.89 DRD3 DRD4 HTR2A
5 response to toxic substance GO:0009636 9.89 DRD2 MAOB SLC6A4
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 HTR2A NRG1 RELN
7 locomotory behavior GO:0007626 9.88 DRD2 DRD3 NRG1 SHANK3
8 memory GO:0007613 9.88 BDNF HTR2A SHANK3 SLC6A4
9 modulation of chemical synaptic transmission GO:0050804 9.85 BDNF DRD2 RELN
10 regulation of synaptic vesicle exocytosis GO:2000300 9.83 DRD2 DTNBP1 HTR2A
11 response to cocaine GO:0042220 9.82 DRD2 DRD3 RGS4
12 regulation of dopamine secretion GO:0014059 9.8 DRD3 DTNBP1 HTR2A
13 response to amphetamine GO:0001975 9.8 DRD2 DRD3 DRD4 RGS4
14 response to morphine GO:0043278 9.79 DRD2 DRD3 RGS4
15 adult behavior GO:0030534 9.79 DRD2 NRXN1 SHANK3
16 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.78 NRXN1 RELN SHANK3
17 arachidonic acid secretion GO:0050482 9.77 DRD2 DRD3 DRD4
18 positive regulation of excitatory postsynaptic potential GO:2000463 9.76 NRXN1 RELN RGS4 SHANK3
19 dopamine receptor signaling pathway GO:0007212 9.74 DRD2 DRD3 DRD4
20 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.73 DRD2 DRD3
21 positive regulation of kinase activity GO:0033674 9.73 DRD4 HTR2A
22 response to pain GO:0048265 9.73 COMT RELN
23 negative regulation of protein secretion GO:0050709 9.73 DRD2 DRD3 DRD4
24 regulation of NMDA receptor activity GO:2000310 9.72 NRXN1 RELN
25 synaptic transmission, dopaminergic GO:0001963 9.72 DRD2 DRD3
26 glial cell differentiation GO:0010001 9.72 NRG1 RELN
27 protein localization to synapse GO:0035418 9.72 NRXN1 RELN
28 positive regulation of long-term synaptic potentiation GO:1900273 9.72 DRD2 RELN SHANK3
29 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
30 vocalization behavior GO:0071625 9.71 NRXN1 SHANK3
31 receptor localization to synapse GO:0097120 9.71 NRXN1 RELN
32 prepulse inhibition GO:0060134 9.71 DRD2 DRD3 NRXN1
33 G protein-coupled receptor internalization GO:0002031 9.7 DRD2 DRD3
34 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.7 DRD3 DRD4
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD3 DRD4
36 neurotransmitter catabolic process GO:0042135 9.69 COMT MAOB
37 behavioral response to ethanol GO:0048149 9.69 DRD2 DRD4
38 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 DRD2 HTR2A
39 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD2 DRD4
40 positive regulation of synapse maturation GO:0090129 9.68 NRXN1 RELN
41 dopamine catabolic process GO:0042420 9.68 COMT MAOB
42 positive regulation of AMPA receptor activity GO:2000969 9.68 RELN SHANK3
43 vocal learning GO:0042297 9.67 NRXN1 SHANK3
44 postsynaptic density protein 95 clustering GO:0097119 9.66 NRXN1 RELN
45 regulation of grooming behavior GO:2000821 9.66 NRXN1 SHANK3
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
47 proline catabolic process GO:0006562 9.65 DAO PRODH
48 NMDA glutamate receptor clustering GO:0097114 9.65 NRXN1 RELN SHANK3
49 learning GO:0007612 9.65 COMT DRD3 NRXN1 RELN SHANK3
50 acid secretion GO:0046717 9.64 DRD2 DRD3

Molecular functions related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 HTR2A
2 adrenergic receptor activity GO:0004935 9.37 DRD2 DRD3
3 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
4 serotonin binding GO:0051378 9.32 HTR2A SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Psychotic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11